Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU

A. R. Cohen, D. D. Pietronigro, H. Cravioto, E. S. Flamm

Research output: Contribution to journalArticle

6 Scopus citations


In an attempt to improve glioma management, an animal model was developed to evaluate the therapeutic efficacy of intra-arterial, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Furthermore, the model was used to study the antitumor activity of D,L-alpha-difluoromethylornithine (DFMO), a polyamine-biosynthesis inhibitor, used both as a single agent and in combination with intra-arterial BCNU. An N-methylnitrosourea-induced gliosarcoma (T9) was transplanted stereotaxically into the right caudate nucleus of male Fischer 344 rats. Animals receiving a single low-dose (5 mg/kg) intracarotid injection of BCNU 9 days following tumor implantation had a 57% increase in life span compared with untreated control rats (p < 0.001). Intracarotid drug delivery was more effective than systemic (intraperitoneal) administration of the same dose of BCNU. When given as a single agent, DFMO demonstrated dose-dependent effectiveness. As part of a combined regimen, DFMO enhanced the antitumor therapeutic activity of both systemic (intraperitoneal) and intraarterial BCNU. Survival times of animals receiving combined DFMO and intra-arterial BCNU were almost double those of untreated controls, and were significantly better than survival times of animals receiving combined DFMO and intraperitoneal BCNU. These findings suggest methods to optimize current clinical chemotherapy for glioma.

Original languageEnglish (US)
Pages (from-to)671-678
Number of pages8
JournalJournal of neurosurgery
Issue number5
StatePublished - Jan 1 1986
Externally publishedYes


ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this